Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article
| Autor: | Kintomo Takakura, Youji Uemae, Takashi Maruyama, Tomokatsu Hori, Yoshikazu Okada, Tadao Ohno, Naohito Yamaguchi, Hiroshi Iseki, Keiki Sato, Akira Matsumura, Katsunori Shimada, Koji Tsuboi, Masao Matsutani, Masahiko Tanaka, Katsuyuki Karasawa, Yoichi Nakazato, Takashi Yamamoto, Yoshihiro Muragaki, Chie Shinohara |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Salvage therapy Cancer Vaccines Disease-Free Survival Clinical endpoint medicine Humans Prospective Studies Prospective cohort study Survival rate Aged business.industry Brain Neoplasms General Medicine Middle Aged Combined Modality Therapy Surgery Radiation therapy Clinical trial Survival Rate Treatment Outcome Tumor progression Concomitant Female Radiotherapy Adjuvant business Glioblastoma |
| Zdroj: | Journal of neurosurgery. 115(2) |
| ISSN: | 1933-0693 |
| Popis: | Object The objective of the present study was analysis of results of the prospective clinical trial directed toward the evaluation of therapeutic efficacy of the administration of autologous formalin-fixed tumor vaccine (AFTV) concomitant with fractionated radiotherapy in cases of newly diagnosed glioblastoma multiforme. Methods Twenty-four patients were enrolled into the clinical trial, while 2 cases were excluded from the final analysis of results. The treatment protocol included aggressive tumor resection, fractionated radiotherapy up to a total dose of 60 Gy, and 3 concomitant courses of AFTV administered with an interval of one week at the late stage of irradiation. Two delayed-type hypersensitivity (DTH) tests were done—one 48 hours before the initial course of vaccination (DTH-1) and one 2 weeks after the third (DTH-2). All but one of the patients received salvage therapy at the time of tumor progression. The defined primary end point was overall survival; secondary end points were progression-free survival and safety of concomitant treatment. Results The median duration of overall survival was 19.8 months (95% CI 13.8–31.3 months). The actuarial 2-year survival rate was 40%. The median duration of progression-free survival was 7.6 months (95% CI 4.3–13.6 months). Overall survival showed a statistically significant association with recursive partitioning analysis class (p < 0.05); progression-free survival showed a statistically significant association with p53 staining index (p < 0.05) and size of DTH-2 response (p < 0.001). AFTV injection concomitant with fractionated radiotherapy was well tolerated by all patients and in no case did treatment-related adverse effects exceed Grade 1 toxicity; adverse effects were limited to local erythema, induration, and swelling at the site of injection. Conclusions The results of this study demonstrate that AFTV treatment concomitant with fractionated radiotherapy may be effective in patients with newly diagnosed glioblastoma. Further clinical testing is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|